Heart failure and asymptomatic left ventricular systolic dysfunction in lymphoma survivors treated with autologous stem-cell transplantation: A national cross-sectional study

Journal of Clinical Oncology

Volumn 33, Issue 24, 2015, Pages 2683-2691

  Murbraech, Klaus ^a   Smeland, Knut B ^a   Holte, Harald ^a   Loge, Jon Håvard ^a,b   Lund, May Brit ^a   Wethal, Torgeir ^c   Holte, Espen ^c   Rösner, Assami ^d   Dalen, Håvard ^c,e   Kvaløy, Stein ^a,b   Falk, Ragnhild S ^a   Aakhus, Svend ^a,c   Kiserud, Cecilie E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e Levanger Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; MELPHALAN;

ADULT; AGE; ARTICLE; ASYMPTOMATIC LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; NONHODGKIN LYMPHOMA; NORWAY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; WHOLE BODY RADIATION; AUTOTRANSPLANTATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; LYMPHOMA; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; PROCEDURES; RISK FACTOR; STEM CELL TRANSPLANTATION;

CROSS-SECTIONAL STUDIES; FEMALE; HEART FAILURE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84940416347     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.8125     Document Type: Article

References (32)

1. Haioun C, Lepage E, Gisselbrecht C, et al: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 15:1131-1137, 1997
2. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
3. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054, 1993
4. Murdych T, Weisdorf DJ: Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant 28:283-287, 2001
5. Sweetenham JW, Santini G, Qian W, et al: High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927-2936, 2001
6. Majhail NS, Bajorunaite R, Lazarus HM, et al: Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol 147:129-139, 2009
7. Wingard JR, Vogelsang GB, Deeg HJ: Stem cell transplantation: Supportive care and long-term complications. Hematology Am Soc Hematol Educ Program 422-444, 2002
8. Chow EJ, Mueller BA, Baker KS, et al: Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 155:21-32, 2011
9. Chow EJ, Wong K, Lee SJ, et al: Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant 20:794-800, 2014
10. Armenian SH, Sun CL, Francisco L, et al: Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 26:5537-5543, 2008
11. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
12. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97:2869-2879, 2003
13. Armenian SH, Sun CL, Shannon T, et al: Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 118:6023-6029, 2011
14. Hertenstein B, Stefanic M, Schmeiser T, et al: Cardiac toxicity of bone marrow transplantation: Predictive value of cardiologic evaluation before transplant. J Clin Oncol 12:998-1004, 1994
15. Frigerio M, Oliva F, Turazza FM, et al: Prevention and management of chronic heart failure in management of asymptomatic patients. Am J Cardiol 91:4F-9F, 2003
16. Davies M, Hobbs F, Davis R, et al: Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: A population based study. Lancet 358:439-444, 2001
17. Wang TJ, Evans JC, Benjamin EJ, et al: Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108:977-982, 2003
18. Smeland KB, Kiserud CE, Lauritzsen GF, et al: High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008. Tidsskr Nor Laegeforen 133:1704-1709, 2013
19. Fulbright JM: Review of cardiotoxicity in pediatric cancer patients: During and after therapy. Cardiol Res Pract 2011:942090, 2011
20. Lancellotti P, Nkomo VT, Badano LP, et al: Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 26:1013-1032, 2013
21. Krokstad S, Langhammer A, Hveem K, et al: Cohort profile: The HUNT Study, Norway. Int J Epidemiol 42:968-977, 2013
22. Dalen H, Thorstensen A, Aase SA, et al: Segmental and global longitudinal strain and strain rate based on echocardiography of 1266 healthy individuals: The HUNT study in Norway. Eur J Echocardiogr 11:176-183, 2010
23. Lang RM, Bierig M, Devereux RB, et al: Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-1463, 2005
24. Hunt SA, Abraham WT, Chin MH, et al: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines - Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119:e391-e479, 2009
25. American Thoracic Society, American College of Chest Physicians: ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167:211-277, 2003
26. Arena R, Myers J, Abella J, et al: Determining the preferred percent-predicted equation for peak oxygen consumption in patients with heart failure. Circ Heart Fail 2:113-120, 2009
27. Hansen JE, Sue DY, Wasserman K: Predicted values for clinical exercise testing. Am Rev Respir Dis 129:S49-S55, 1984
28. Drafts BC, Twomley KM, D'Agostino R Jr, et al: Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 6:877-885, 2013
29. Avilés A, Neri N, Nambo JM, et al: Late cardiac toxicity secondary to treatment in Hodgkin's disease: A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 46:1023-1028, 2005
30. Zhang S, Liu X, Bawa-Khalfe T, et al: Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18:1639-1642, 2012
31. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878-1886, 2007
32. Tsai HR, Gjesdal O, Wethal T, et al: Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. Am J Cardiol 107:472-477, 2011